A systematic review of five clinical trials involving 21,947 HF patients showed that SGLT2 inhibitors reduce the risk of primary composite HF in both men and women, but that the benefits are less pronounced in women [154]. This evidence concerns the gene SLC5A2 and hydrops fetalis.